Jemperli (Dostarlimab) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to advances in immune checkpoint inhibitors, rising cancer prevalence, clinical success in endometrial cancer, increased oncology research funding, hospital adoption of immunotherapy.

The growth in the forecast period can be attributed to expansion into additional cancer indications, increasing use of combination therapies, growing biomarker testing adoption, rising oncology healthcare spending, improved survival outcomes. Major trends in the forecast period include expansion of pd-1 inhibitor therapies, growth in cancer immunotherapy adoption, personalized oncology treatment strategies, combination immunotherapy regimens, biomarker-driven cancer care.

The rising incidence of cancer is expected to drive the growth of the Jemperli (dostarlimab) market in the future. The increase in cancer cases can be attributed to factors such as poor nutrition, smoking, obesity, environmental pollution, increased screening, an aging population, and lifestyle changes, particularly among younger individuals. Jemperli (dostarlimab) is used to treat advanced or recurrent endometrial cancer, especially in patients with mismatch repair deficiency, by enhancing the immune response against cancer cells when used in combination with chemotherapy. For example, a report published in August 2024 by the Australian Institute of Health and Welfare, an Australian national agency for health and welfare statistics, projects that by 2034, Australia will have approximately 209,000 new cancer diagnoses, a significant rise from the estimated 169,000 cases expected in 2024. This increase reflects the impact of a growing population and rising cancer rates. Furthermore, cancer is expected to account for about 3 out of every 10 deaths in the country in 2024. Therefore, the growing cancer incidence is contributing to the expansion of the Jemperli (dostarlimab) market.

The rising demand for personalized medicine is expected to further drive the growth of the Jemperli (dostarlimab) market. Personalized medicine tailors treatment and healthcare decisions based on the individual characteristics, needs, and genetic profile of each patient. The increasing demand for personalized treatments is being driven by advancements in genomics, targeted therapies, and the growing prevalence of chronic diseases that necessitate more precise treatment strategies. Personalized medicine leverages Jemperli (dostarlimab) by targeting specific genetic mutations in tumors, such as mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) cancers, to improve treatment effectiveness. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based non-profit organization, reported that in 2023, the FDA approved 16 new personalized treatments for rare diseases, up from six in 2022. Among these, seven cancer drugs and three treatments for other conditions were included. Therefore, the increasing demand for personalized medicine is contributing to the expansion of the Jemperli (dostarlimab) market.

A key trend in the Jemperli (dostarlimab) market is focused on innovations aimed at advancing cancer treatment, such as chemotherapy. Chemotherapy, a cancer treatment, utilizes powerful drugs to destroy rapidly growing cells, primarily targeting cancer cells. It can be employed as either a curative or palliative approach and is often combined with other therapies to enhance effectiveness and manage symptoms. For example, in July 2023, GlaxoSmithKline (GSK) plc, a UK-based biopharma company, announced that the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for Jemperli (dostarlimab), seeking to expand its use in combination with chemotherapy for treating adult patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

Major companies operating in the jemperli (dostarlimab) market are GlaxoSmithKline (GSK) Plc.

North America was the largest region in the jemperli (dostarlimab) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the jemperli (dostarlimab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the jemperli (dostarlimab) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the jemperli market by increasing costs for monoclonal antibody production inputs, specialized manufacturing equipment, and cold-chain distribution. Oncology hospitals and specialty clinics in north america and europe are most affected due to high biologics import dependence. Treatment costs and procurement complexity have increased. At the same time, tariffs are accelerating domestic biologics manufacturing and strengthening regional immunotherapy supply chains.

The jemperli (dostarlimab) market research report is one of a series of new reports that provides jemperli (dostarlimab) market statistics, including jemperli (dostarlimab) industry global market size, regional shares, competitors with a jemperli (dostarlimab) market share, detailed jemperli (dostarlimab) market segments, market trends and opportunities, and any further data you may need to thrive in the jemperli (dostarlimab) industry. This jemperli (dostarlimab) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Jemperli (dostarlimab) is a monoclonal antibody used in cancer immunotherapy. It works as a PD-1 inhibitor, blocking the interaction between PD-1 and its ligands, thereby enhancing the immune system's ability to fight cancer. It is primarily approved for treating certain types of endometrial and non-small cell lung cancer.

The main patient demographics of jemperli (dostarlimab) are adult patients, elderly patients, and high-risk groups. Adult patients are individuals aged 18 years or older. Jemperli (dostarlimab) treats adult patients with specific types of advanced or recurrent cancers, particularly endometrial or mismatch repair-deficient tumors, by enhancing the immune system's ability to attack cancer cells. It has applications in cancer treatment and combination therapy and distributed through hospitals, specialty clinics, pharmacies, and online pharmacies.

The jemperli (dostarlimab) market consists of sales of jemperli (dostarlimab-gxly) injection and jemperli plus chemotherapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.